Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

NCT07350824 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

276

Enrollment

OTHER

Sponsor class

Conditions

HCC
Minimal Residual Disease
Recurrence

Interventions

DRUG: Adjuvant PD-1 inhibitors
OTHER: Active monitoring

Sponsor

Tongji Hospital